Mr. Bradley James Heim is a pharmacist who is specialized in Oncology in Akron, Ohio. Patients can reach him at 224 W Exchange St., Akron or contact him on 330-344-6159. Active license number of Mr. Bradley James Heim is 03313325 for Oncology in Ohio. Mr. Bradley James Heim is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Mr. Bradley James Heim speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Mr. Bradley James Heim
Specialization:
Oncology
Credentials:
RPH
Gender:
Male
Location:
224 W Exchange St., Akron, Ohio, 44302
Phone:
330-344-6159
Fax:
330-253-3651
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Mr. Bradley James Heim are as mentioned below.
NPI Number:
1578620969
NPI Enumeration Date:
03 Jan, 2007
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Mr. Bradley James Heim are as mentioned below.
Specialization
License Number
State
Status
Oncology
03313325
Ohio
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
136 Fox Ridge Way, Tallmadge, Ohio
Zip:
44278
Phone Number:
330-630-2591
Fax Number:
330-253-3651
Patients can reach Mr. Bradley James Heim at 224 W Exchange St., Akron, Ohio or can call on phone at 330-344-6159.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.